Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 12, 2005

View Archived Issues

New phase IIb study for CS-917 in type 2 diabetes

Japanese phase II study of BAY-43-9006 for advanced renal cell carcinoma

Valeant submits complete response for Zelapar

PA-457 awarded fast track status for HIV

Fast track designation for epratuzumab in lupus

Approvable letter for Bonefos for adjuvant treatment of breast cancer

Sirna launches programs to treat asthma and diabetes with RNAi technology

VX-680 enters phase I study in solid tumor patients

IND submission for HCV-796

Peplin reports positive phase I results for PEP-005 Topical

Priority review for Aceon sNDA

New phase III trial evaluates Velcade in newly diagnosed multiple myeloma

Dosing completed in phase II study of Puricase for severe gout

Human Genome Sciences cleared for phase I study of CCR5 mAb for HIV

Sangamo submits IND for SB-509 to treat diabetic neuropathy

Treatment phase begins in SHEPHERD study of eculizumab for PNH

gamma-Tocopherol, a vitamin E form, is effective against prostate cancer

Therapeutic vaccine protects against HIV-induced autoimmunity

HCV NS3-NS4A protease inhibitor and INF-alpha synergistically inhibit HCV replication in vitro

Azithromycin improves coronary microcirculation in CAD patients

Low menaquinone levels related to coronary heart disease

Thiazolidinedione derivatives claimed by Incyte

Ono discloses a series of CCR5 receptor antagonists

Akt inhibitors prepared and tested at Lilly

Kalypsys patent covers novel PPAR modulators for obesity, diabetes, etc.

Tachykinin NK2 antagonists in early development at Menarini

Scientists at Enanta report novel agents for hepatitis C infections

Muscarinic M1 receptor antagonists emerge from research at Lilly

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...